QuidelOrtho reports Q4 adjusted EPS 46c, consensus 42c

Reports Q4 revenue $724M, consensus $700.09M. “In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagnostics business,” said CEO Brian Blaser. “Our Labs, Immunohematology and Cardiac businesses delivered consistent growth, while cost-savings initiatives drove meaningful margin expansion. As a result, we are well positioned to generate substantially stronger free cash flow in 2026, which we believe more accurately reflects the earnings power of our business.”